EchoNext
AI-powered ECG analysis to detect undiagnosed structural heart disease
Software · Cloud SaaSCompany source
Company profile
About Pathway Labs
Pathway Labs is a healthcare AI company that has developed EchoNext, a breakthrough cardiac biomarker platform that transforms the standard 12-lead electrocardiogram into a next-generation diagnostic tool. The company's AI technology reads compatible 12-lead ECGs to detect structural heart disease and other cardiac conditions that are invisible to traditional human interpretation. With over 500,000 patients tested to date across 20 hospitals, EchoNext has demonstrated a 91% increase in new clinically significant diagnoses compared to routine clinical care. The platform detects multiple forms of structural heart disease including LV and RV systolic dysfunction, valve diseases (aortic stenosis and regurgitation, mitral regurgitation, tricuspid regurgitation, pulmonic regurgitation), severe left ventricular hypertrophy, pulmonary hypertension, and pericardial effusion. EchoNext integrates seamlessly into existing clinical workflows, requiring no new hardware or dashboards, and delivers flagged clinical reports directly to ordering clinicians with plain-language risk tiers and recommended next steps. The company's research has been published in leading medical journals including Nature, NEJM AI, JACC, and Circulation, with their Nature 2025 paper becoming the most-read cardiac AI paper of all time. Pathway Labs enables health systems to screen for structural heart disease at population scale, similar to cancer screening—broadly, cheaply, and early.
Company description Pathway Labs official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Pathway Labs?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Aortic regurgitation
- Aortic stenosis
- Hidden arrhythmia
- LV systolic dysfunction
- Mitral regurgitation
- Pericardial effusion
- Pulmonary hypertension
- Pulmonic regurgitation
- RV systolic dysfunction
- Severe left ventricular hypertrophy
- Silent ischemia
- Structural heart disease
- Tricuspid regurgitation
Who it serves
- Cardiology teams
- Health Systems
- Hospitals
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Published most-read cardiac AI paper of all time in Nature 2025. Achieved world-first AI-detected procedures including TAVR, MVR, and Heart Transplant. Tested 500K+ patients across 20 hospitals. Multiple publications in 2024-2026 in Nature, NEJM AI, JACC, Circulation, and European Heart Journal.
Partnerships
Recorded partners
- NewYork-Presbyterian
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
91% increase in new clinically significant diagnoses
Compared to routine clinical care
78% accuracy vs 64% for expert readers
Study of 13 cardiologists reading ~3,000 ECGs
2× positive predictive value
EchoNext high-risk patients vs first-time echos ordered through routine clinical care
500K+ patients tested
Across 20 hospitals to date
20 hospitals
Detecting undiagnosed structural heart disease at scale
2× positive predictive value of EchoNext high-risk patients vs. first-time echos ordered through routine clinical care
Multiple health systems
AI detection leading to world-first procedures including TAVR, MVR, and heart transplant
Three world-first procedures attributed to AI detection; 78% accuracy vs 64% for expert cardiologist readers
NewYork-Presbyterian
Screening for structural heart disease using AI-enhanced ECG analysis
500K+ patients tested to date, 91% increase in new clinically significant diagnoses
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Pathway Labs
Recent articles published on Pathway Labs's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
The Cardiology AI Explosion: Why 225 FDA Clearances Are Creating a Hospital Headache
As cardiovascular AI tools flood the market, health systems face a new challenge—managing portfolios instead of products.
Clinical AI · Sep 8, 2026
AI Screening Tool Outperforms Cardiologists at Detecting Silent Heart Disease from Standard ECGs
FDA-cleared EchoNext analyzes routine electrocardiograms to identify six structural heart conditions before symptoms appear, achieving 77% accuracy compared to 64% for specialist physicians.
Clinical AI · Jul 25, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.